REG - Burning Rock Biotech - BNR Schedules 22Q4 and Full Year ER on March 28

Burning Rock BiotechAnnouncement

07/03/2023 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230307:nRSG1388Sa&default-theme=true

RNS Number : 1388S  Burning Rock Biotech Limited  07 March 2023

Burning Rock Schedules Fourth Quarter and Full Year 2022 Earnings Release on
March 28, 2023

GUANGZHOU, China, March 7, 2023-Burning Rock Biotech Limited (NASDAQ: BNR and
LSE: BNR, the "Company" or "Burning Rock"), a company focused on the
application of next generation sequencing (NGS) technology in the field of
precision oncology, today announced that it plans to release its unaudited
financial results for the fourth quarter and full year 2022 before the U.S.
market opens on March 28, 2023. Following the release, company management will
host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same
day to discuss its financial results for the fourth quarter and full year
2022.

Please register in advance of the conference using the link provided below and
dial in 15 minutes prior to the call, using participant dial-in numbers and
unique registrant ID which would be provided upon registering.

PRE-REGISTER LINK:

https://register.vevent.com/register/BI1cc3eb383ecf42c6969319f9e9cdd02c
(https://register.vevent.com/register/BI1cc3eb383ecf42c6969319f9e9cdd02c) .

Additionally, a live and archived webcast of the conference call will also be
available on the company's investor relations website at
http://ir.brbiotech.com (http://ir.brbiotech.com) or through link
https://edge.media-server.com/mmc/p/tx2a7ju9
(https://edge.media-server.com/mmc/p/tx2a7ju9) .

A replay of the webcast will be available for 12 months via the same link
above.

Please visit the Company's investor relations website at
https://ir.brbiotech.com/news-events/news-releases on March 28, 2023 to view
the earnings release prior to the conference call.

 

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
Guard Life via Science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) NGS-based cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: www.brbiotech.com
(https://www.globenewswire.com/Tracker?data=oKHzdzt5kGL2zhfVeWLHG4RSCd0Qq3w7WMdcV1zEwpNpJxNTAAS6ngZAI3P9e0D7buq-KTNsAu8r4Xe7JWAAkQ==)
.

 

Safe Harbor Statement

This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes," "estimates,"
"target," "confident" and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports to the SEC,
in its annual report to shareholders, in press releases and other written
materials and in oral statements made by its officers, directors or employees
to third parties. Statements that are not historical facts, including
statements about Burning Rock's beliefs and expectations, are forward-looking
statements. Such statements are based upon management's current expectations
and current market and operating conditions, and relate to events that involve
known or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock's control.
Forward-looking statements involve risks, uncertainties and other factors that
could cause actual results to differ materially from those contained in any
such statements. All information provided in this press release is as of the
date of this press release, and Burning Rock does not undertake any obligation
to update any forward-looking statement as a result of new information, future
events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORZZGGFRNNGFZG